Dr. Lal Pathlabs’s IPO, through which the diagnostic chain raised Rs. 638 crore, was over-subscribed 33.41 times.
After receiving overwhelming response from the retail as well as institutional investors for their initial public offerings (IPOs), both Dr. Lal Pathlabs and Alkem Laboratories today opened 31.42% and 30.36% higher over their respective issue price of Rs. 550 and Rs. 1,050.
Shares of Dr. Lal Pathlabs are currently trading higher at Rs. 778 after opening higher at Rs. 717 over its issue price. It touched a high of Rs. 782 and a low of Rs. 715.50. So far, 25.21 lk shares have changed hands on BSE.
Dr. Lal Pathlabs’s IPO, through which the diagnostic chain raised Rs. 638 crore, was over-subscribed 33.41 times. In addition, the company raised Rs. 191 crore via offering shares at Rs. 550 apiece to the anchor investors.
The promoter and promoter group raised the aforementioned amount via an offer for sale issue of 1.16 crore equity shares. According to the company’s Chairman Dr Arvind Lal, the IPO proceeds will not be utilize for any particular purpose as of now. The company has ample cash to meet business expenses and expansion costs.
The Delhi-based company has a pan-India presence with a strong network of 172 clinical laboratories 1,554 patient service centers and over 7,000 pickup points. The company also plans to expand its footprints in neighboring Asian countries.
Shares of Alkem Lab are currently trading lower at Rs. 1,378.50 after opening at Rs. 1,380. It touched a high of Rs. 1,401.40 and a low of Rs. 1,355.40. So far, 14.17 lk shares have changed hands on BSE.
Shares of Alkem Laboratories has seen a robust debut on the exchanges Wednesday. The pharma stock is listed at Rs 1380 per share, up 31 percent from its issue price of Rs 1050 per share. It touched intraday high of Rs 1399 per share on the NSE.
Alkem Laboratories, India’s fifth largest domestic drug maker, raised Rs. 1,350 crore via its IPO which was open from December 8-10, 2015. The public issues was over-subscribed 44.29 times. The QIB quota was over-subscribed by 57.19 times, while in non-institutional segment, the issue was over-subscribed by 129.96 times.
Reinstating the faith of retain investors in the primary market, the IPO received 3.17 times subscription from retail investors.
Shares of Dr. Lal Pathlabs are currently trading higher at Rs. 778 after opening higher at Rs. 717 over its issue price. It touched a high of Rs. 782 and a low of Rs. 715.50. So far, 25.21 lk shares have changed hands on BSE.
Dr. Lal Pathlabs’s IPO, through which the diagnostic chain raised Rs. 638 crore, was over-subscribed 33.41 times. In addition, the company raised Rs. 191 crore via offering shares at Rs. 550 apiece to the anchor investors.
The promoter and promoter group raised the aforementioned amount via an offer for sale issue of 1.16 crore equity shares. According to the company’s Chairman Dr Arvind Lal, the IPO proceeds will not be utilize for any particular purpose as of now. The company has ample cash to meet business expenses and expansion costs.
The Delhi-based company has a pan-India presence with a strong network of 172 clinical laboratories 1,554 patient service centers and over 7,000 pickup points. The company also plans to expand its footprints in neighboring Asian countries.
Shares of Alkem Lab are currently trading lower at Rs. 1,378.50 after opening at Rs. 1,380. It touched a high of Rs. 1,401.40 and a low of Rs. 1,355.40. So far, 14.17 lk shares have changed hands on BSE.
Shares of Alkem Laboratories has seen a robust debut on the exchanges Wednesday. The pharma stock is listed at Rs 1380 per share, up 31 percent from its issue price of Rs 1050 per share. It touched intraday high of Rs 1399 per share on the NSE.
Alkem Laboratories, India’s fifth largest domestic drug maker, raised Rs. 1,350 crore via its IPO which was open from December 8-10, 2015. The public issues was over-subscribed 44.29 times. The QIB quota was over-subscribed by 57.19 times, while in non-institutional segment, the issue was over-subscribed by 129.96 times.
Reinstating the faith of retain investors in the primary market, the IPO received 3.17 times subscription from retail investors.
No comments:
Post a Comment